Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

On November 8, 2024 Autolus, Inc. (“Autolus”) announced that the FDA has approved AUCATZYL (obecabtagene autoleucel) for the treatment of ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Lawyers for Sean ‘Diddy’ Combs say prosecutors have engaged in “outrageous government conduct” by using materials seized from ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

CD19 and BCMA are expressed on normal cells as well as malignant cells, so the CAR T-cell therapies eliminate some healthy ...

Wichita Public Schools implemented a new cell phone policy last year, and held a discussion on its efficacy Monday.

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.